Skip to main content

Table 3 Cost-effectiveness analysis results (base case)

From: The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis

Screening strategy 1st and 2nd trimester screening (current screening) NIPT as contingent testing NIPT as first-line testing
Effectiveness
No of women undergoing 1st and 2nd trimester screening tests 66,799 66,799 1336
No of women undergoing NIPT 0 3152 66,799
No of NIPT with a positive result 0 251 280
No of ITa 3275 579 700
No of procedure-related miscarriages 23 4 5
No of T21 cases detected 271 269 296
Costs
1st and 2nd trimester screening tests €5,292,716 €5,292,716 €101,536
NIPT €0 €1,802,350 €40,114,800
IT €3,093,565 €546,923 €661,220
Hospitalisation due to amniotic fluid leakage and pregnancy termination owing to T21 €515,591 €469,362 €518,389
Total costs €8,901,872 €8,111,351 €41,395,745
Economic analysis NIPT as first-line testing vs 1st and 2nd trimester screening NIPT as contingent testing vs 1st and 2nd trimester screening NIPT as first-line testing vs NIPT as contingent testing
Incremental cost €32,494,073 €− 790,521 €33,284,594
Incremental effectiveness (T21 extra cases detected) 25 − 2 27
ICER (€/T21 extra case detected) 1,299,763 1,232,763
  1. ICER, incremental cost-effectiveness ratio; IT, invasive tests; NIPT, non-invasive prenatal testing; T21, trisomy 21
  2. aOut of the total number of invasive diagnostic tests performed, 271 correspond to pregnant women with a NT ≥ 3.5 mm (considered high-risk)